April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
The Ocular Pharmacokinetics and Bioavailability of Puerarin in the Microemulsion With Ion-Triggered in situ Gelling Ophthalmic Delivery System
Author Affiliations & Notes
  • L. Zhang
    Henan Eye Institute, zhengzhou, China
  • J. Zhang
    Henan Eye Institute, zhengzhou, China
  • L. Wang
    Henan Eye Institute, zhengzhou, China
  • T. Zhou
    Henan Eye Institute, zhengzhou, China
  • H. Xia
    Henan Eye Institute, zhengzhou, China
  • Footnotes
    Commercial Relationships  L. Zhang, None; J. Zhang, None; L. Wang, None; T. Zhou, None; H. Xia, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5977. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Zhang, J. Zhang, L. Wang, T. Zhou, H. Xia; The Ocular Pharmacokinetics and Bioavailability of Puerarin in the Microemulsion With Ion-Triggered in situ Gelling Ophthalmic Delivery System. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5977.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the ocular pharmacokintics and conreal penetration of puerarin (PU) after topical application of an ophthalmic solution based on microemulsion with ion-triggered in situ gelling system for puerarin, which is an osajin isoflavone extracted from radix of Pueraria lobata and poorly soluble in water.

Methods: : A microemulsion containing ion-triggered in situ gelling vehicle for ophthalmic delivery of 1% PU (ME-G-PU) and a microemulsion containing 1% PU (ME-PU) with the same pH (5.6) were prepared, respectively. PU solution containing polyvinyl pyrrolidone (PVP-PU) with the same pH was prepared as a control. A single dose of ME-G-PU, ME-PU or PVP-PU was applied to rabbits. Aqueous humor and cornea were collected after application at 5, 15, 30, 60, 120, 180, 240, 360and 480 min. PU concentrations were determined by HPLC with a fluorescence detector after extraction.

Results: : After topically applying ME-G-PU, the PU levels in aqueous humor were significantly increased at 5~480min compared with those of ME-PU and PVP-PU at the corresponding time points (p < 0.05) excluding with that of PVP-PU at 360 min. The highest levels of PU in aqueous humor (Cmax, 689.34 ± 449.42ng/mL) were obtained after 60 min application of ME-G-PU, The area under the concentration-time in aqueous humor over 480min (AUC0-480) for ME-G-PU was increased compared with ME-PU and PVP-PU (108162.3ng/mL•min vs 14638.5 and 36635.5 ng/mL•min). The ME-G-PU produced an over seven-fold and three-fold bioavailability (AUC0-120) increase in aqueous humors over the ME-PU and PVP-PU, respectively. Peak PU concentration in cornea (92932.40 ± 6992.15 ng/g) was achieved within 5 min after instillation of ME-G-PU, the PU levels in cornea were significantly increased at 5~180min compared with those of ME-PU and PVP-PU at the corresponding time points (p < 0.05). The AUC0-480 in cornea for ME-G-PU was increased compared with ME-PU and PVP-PU (599901.0 ng/g•min, 190967.5 and 215346.7 ng/g•min). The ME-G-PU produced an over three-fold bioavailability (AUC0-120) increase in corneas over the ME-PU and PVP-PU, respectively.

Conclusions: : ME-G-PU is superior to ME-PU and PVP-PU by increasing ocular bioavailability.

Keywords: cornea: basic science • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×